HOW IT-001 WORKS

Rethinking how immunotherapy reaches the tumor.

The problem with many immunotherapies isn’t the drug. It’s the delivery.

Why IL-12

A powerful cytokine held back by toxicity.

IL-12 activates both the innate and adaptive immune systems. It can turn immunologically “cold” tumors “hot” and train the immune system to attack distant tumors.

But promising results didn’t translate to the clinic. When given systemically, the highest tolerable dose wasn’t effective, and trials were halted due to toxicity. IL-12 was dose-limited.

Why intratumoral injections fail

Injecting into the tumor isn’t enough.

Intratumoral injections generate infusion pressures that are high enough to fracture tissue, and since injections are conventionally saline-based, fluid leaks away into the bloodstream or back out along the needle track.

In one clinical study, only one of four injections stayed within the targeted liver tumor.* Preclinically, directly injected cytokines are undetectable within 24 hours.**

* Sheth et al., JAMA Netw Open, 2020 Jul 1;3(7):e207911

** Mantooth et al., J Control Release, 2025 Jul 10;383:113761

XCSgel stays where it’s injected.

The dye leaks back along the needle track and out of the target. If this were a drug, there would be limited accumulation within the tumor and high systemic exposure.

Saline injection

XCSgel is easily injectable and stays localized at the injection site. Drug stays in the tumor where it can have the intended therapeutic effect, rather than causing adverse, toxic side effects.

XCSgel injection

XCSgel is a chitosan-based hydrogel. It solves the leakage problem that has been holding back intratumoral injections because it is shear-thinning: it’s a gel in the syringe that liquefies as it is pushed through the needle and immediately re-forms a gel at the injection site.

Publications

Journal of Controlled Release

An injectable hydrogel enhances intratumoral retention and antitumor efficacy of cytokine immunotherapy in murine triple negative breast tumor models

A single injection of XCSgel co-formulated with IL-12 eliminated 86% of treated tumors and 67% of untreated distant tumors in a mouse model of triple-negative breast cancer, and cured mice resisted tumor rechallenge. These results demonstrate that XCSgel-IL12 potentiates an abscopal response, induces durable anti-tumor immunity, and may be an effective therapy for both locally aggressive and metastatic cancers. 

DOI: 10.1016/j.jconrel.2025.113761

ACS Biomaterials Science & Engineering

Characterization of an Injectable Chitosan Hydrogel for the Tunable, Localized Delivery of Immunotherapeutics

XCSgel is a crosslinked chitosan hydrogel designed for localized delivery of immunotherapies. It is shear-thinning, self-healing, biocompatible and imageable, and it provides tunable, sustained release of biologics. XCSgel is well-tolerated and causes only transient inflammation.